Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine and Thiamine in Ischemic Heart Failure
NCT05873881Phase 3Recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of colchicine and thiamine in heart failure (HF) (4 arms), sponsored by Hamilton Health Sciences. Primary endpoints: Time to first occurrence of a CV death, a HF event, MI, stroke, or arterial revascularization at 3.5 years and Time to first occurrence of a CV death, or a HF event at 3.5 years. Started Jan 2024; status: recruiting.
02
Drugs
colchicinethiamine
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05873881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873881.